Study of Immunotherapy to Treat Advanced Prostate Cancer

Clinical Trial ID NCT00861614

PubWeight™ 83.34‹?›

🔗 Visit the page for NCT00861614

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012 8.46
2 Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011 6.44
3 Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014 5.89
4 Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013 2.35
5 Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010 2.28
6 Antibody-based therapeutics to watch in 2011. MAbs 2011 2.00
7 Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011 1.98
8 CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013 1.71
9 Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 2011 1.60
10 The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 2011 1.55
11 Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer 2012 1.47
12 A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 2012 1.24
13 Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 2011 1.12
14 Overview of the latest treatments for castration-resistant prostate cancer. Nat Rev Urol 2013 1.12
15 Prostate cancer immunotherapy. Clin Cancer Res 2011 1.11
16 Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol 2012 1.09
17 Current status of immunological therapies for prostate cancer. Curr Opin Urol 2010 1.06
18 Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2009 1.04
19 Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc J 2011 1.04
20 Radiation survivors: understanding and exploiting the phenotype following fractionated radiation therapy. Mol Cancer Res 2012 1.02
21 T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. Trends Mol Med 2011 1.01
22 Molecular pathways and targets in prostate cancer. Oncotarget 2014 1.00
23 Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther 2010 1.00
24 Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother 2011 0.97
25 The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2013 0.97
26 Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol 2014 0.96
27 From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev Vaccines 2011 0.94
28 Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol 2012 0.93
29 Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med 2013 0.93
30 Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell Death Dis 2013 0.93
31 Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2011 0.93
32 Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. Front Immunol 2015 0.92
33 Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Curr Opin Oncol 2012 0.92
34 Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene 2013 0.91
35 Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist 2011 0.90
36 Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer 2012 0.89
37 Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer. Int J Oncol 2011 0.88
38 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
39 Cell mates: paracrine and stromal targets for prostate cancer therapy. Nat Rev Urol 2013 0.87
40 Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Ther Adv Vaccines 2014 0.86
41 Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. Prostate Cancer Prostatic Dis 2014 0.86
42 Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urol Oncol 2016 0.86
43 Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. J Transl Med 2013 0.85
44 Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J 2013 0.84
45 Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. Asian J Androl 2014 0.84
46 Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Vaccine 2011 0.84
47 Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013 0.83
48 The current and emerging role of immunotherapy in prostate cancer. Clin Genitourin Cancer 2010 0.83
49 Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 2012 0.81
50 Current status of immunological approaches for the treatment of prostate cancer. Curr Opin Urol 2012 0.81
51 Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer 2016 0.81
52 Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer. Clin Med Insights Oncol 2012 0.80
53 Post-docetaxel therapy in castration resistant prostate cancer - the forest is growing in the desert. Ther Adv Urol 2012 0.80
54 Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr Treat Options Oncol 2014 0.79
55 Ipilimumab. Drugs R D 2010 0.79
56 Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol 2011 0.78
57 A changing landscape in castration-resistant prostate cancer treatment. Front Endocrinol (Lausanne) 2012 0.78
58 Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'? Oncology (Williston Park) 2014 0.78
59 Immunotherapy for prostate cancer enters its golden age. Clin Med Insights Oncol 2012 0.77
60 The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer. Rev Urol 2014 0.77
61 Commentary on: "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial." Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Departments of Urology and Immunology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA, Electronic address:; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, Baltimore, MD, USA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; Institut Gustave Roussy, University of Paris-Sud, Villejuif, France; Institut Gustave Roussy, Villejuif, France; VU University Medical Centre, Amsterdam, Netherlands; Vienna General Hospital, Medical University Vienna, Vienna, Austria; Institut Bergonié, Bordeaux, France; CHU Caremeau, Nimes, France; Centro Médico Austral, Buenos Aires, Argentina; Centre Jean Perrin, Clermont-Ferrand, France; St John of God Hospital, Subiaco, WA, Australia; University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; Hospital de Caridade de Ijuí, Ijuí, Brazil; Nottingham University Hospital, Nottingham, UK; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania; Hospital Británico de Buenos Aires, Buenos Aires, Argentina; Herlev Hospital, Herlev, Denmark; Odense University Hospital, Odense, Denmark; University of Texas MD Anderson Cancer Center, Houston, Urol Oncol 2015 0.76
62 Synergy of cancer immunotherapy and radiotherapy. Aging (Albany NY) 2015 0.76
63 Castrate-resistant prostate cancer: postdocetaxel management. Curr Opin Urol 2013 0.75
64 Management of metastatic castration-resistant prostate cancer. Eur Urol Rev 2011 0.75
65 The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patients. P T 2012 0.75
66 Is the induction of tumor cell senescence the key to a good irradiated tumor vaccine? Mol Ther 2012 0.75
67 Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer? Cancer Med 2013 0.75
Next 100